[Some investigations on cefadroxil dry syrup (author's transl)]

Area of Science:

• Pharmacology and Microbiology
• Pediatric Infectious Diseases

Context:

• A group beta-hemolytic Streptococcus (GABHS) is a common pathogen causing various pediatric infections.
• Limited treatment options and emerging resistance necessitate evaluation of effective antimicrobial agents.
• Cefadroxil (CDX) is a cephalosporin antibiotic with potential utility in treating GABHS infections.

Purpose:

• To evaluate the in vitro susceptibility of GABHS to cefadroxil (CDX).
• To assess the clinical efficacy and safety of CDX in treating pediatric patients with GABHS infections.
• To compare the therapeutic outcomes of CDX with cephalexin (CEX).

Summary:

• Cefadroxil exhibited a minimum inhibitory concentration (MIC) of 0.05-0.2 µg/ml against GABHS, indicating greater susceptibility than cephalexin (CEX) and cefaclor (CCL).
• Oral administration of CDX resulted in higher serum levels compared to Cefaclor (CCL) and good urinary excretion, similar to CEX and CCL.
• Clinical trials involving 69 pediatric patients with scarlet fever, tonsillitis, and other infections showed a 100% efficacy rate for CDX, with rapid fever reduction and bacterial clearance, outperforming CEX in bacterial eradication.

Impact:

• Cefadroxil dry syrup is a safe and effective treatment option for acute pediatric infections caused by susceptible pathogens, including GABHS.
• The study supports the use of CDX in pediatric infectious disease management, offering a favorable alternative with a 100% clinical success rate and no observed side effects.
• CDX demonstrates significant advantages in bacterial clearance and clinical outcomes compared to existing treatments like CEX.